Matching geography Reports matching your search in: Join Alert Me now!Receive bi-weekly email alerts on new market research Sign up today!
|
Pharmaceuticals: market research reports
The pharmaceutical industry is a $1 trillion-dollar sector and has been a major engine of economic growth and scientific advancement for decades. The industry encompasses a wide range of enterprises including large ethical drug multi-nationals (so-called Big Pharma), mid-sized specialty pharmaceutical companies, generic manufacturers, virtual pharmas, small biotechnology and biopharmaceutical firms, and all the various ancillary support and service companies that provide contract research, regulatory guidance, contract sales, and manufacturing technologies and raw materials.
Although growth has not been as robust in recent years—mainly due to price pressures, uncertainty in regulatory/reform measures, and weak drug pipelines— the demographic and structural drivers of demand in healthcare still exist: namely, the continued aging of the global population and the increasing sophistication and wealth of developing nations. Shifting epidemiology patterns and outbreaks, along with new challenges in chronic disease, cancer, heart disease, and degenerative disease will continue to impel the need for ever-better medicines. New understanding and technologies in drug delivery, and most especially in the fields of genomics, proteomics, and molecular biology generally, also hold promise for better therapeutics and a revival of profits.
Pharmaceuticals market research reports and industry analysis
Romania Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... are a small improvement, though definitely not what producerswould have wanted ideally. With part of the objective of the claw-back tax to improve the timeliness ofpayments for reimbursed medicines, which has been a major difficulty ...
|
more...
|
$1,175.00
|
Serbia Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... consumption is also expected to rise. However, financial inefficiencies within the healthinsurance system mean that the National Health Insurance Institution (RZZO) is unable to always meet itsobligations on time, leaving patients to pay for formerly ...
|
more...
|
$1,175.00
|
Zambia Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... by both NGOs and international investors as a sign that Zambia istaking its commitment to healthcare seriously. The country suffers from a burden of both communicableand non-communicable diseases, with a high incidence of HIV and ...
|
more...
|
$1,175.00
|
Brazil Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... and pharmaceutical industry to reduce thefinancial burden of diseases, and the country's private healthcare sectors provide opportunities forforeign companies. However, the increasing drug rebate level has significantly undermined the profitsrecorded by generic drugmakers. The more ...
|
more...
|
$1,175.00
|
Central America Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... opportunities forgeneric drugmakers from neighbouring Latin American countries and India. We highlight that Costa Ricaand Panama can be the premier countries in the region for foreign drugmakers to expand their presence. Headline Expenditure Projections Pharmaceuticals: ...
|
more...
|
$1,175.00
|
Hungary Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... margins and introduced insecurityto an already difficult economic environment, and we continue to expect a contraction in the size of theHungarian pharmaceutical market in 2012 and 2013. Consequently, Hungarian drugmakers will have tobecome even more ...
|
more...
|
$1,175.00
|
Lithuania Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... with the market expected to increase by a local currency margin of 2.5%year-on-year (y-o-y) to reach LTL1.68bn (US$618mn) in 2012 at consumer prices. However, in US dollarterms, the market's value will shrink by 6.3%, indicating ...
|
more...
|
$1,175.00
|
Portugal Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... Portugal has already made considerable savings in the healthcaresectors, with changes such as the introduction of e-prescriptions and prescribing by active ingredients,changes to reference pricing, reductions in pharmacy margins and price cuts just some of ...
|
more...
|
$1,175.00
|
Qatar Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... is anticipated the drug manufacturers will (in our view eventually) help curbreliance on imports and lower prices of retail medicines in the country as a result of increased localcompetition, according to Dr Aisha al-Ansari of ...
|
more...
|
$1,175.00
|
Jordan Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... generic medicines, in tandem withprice-reduction strategies. Nevertheless, the expansion of government provision and the higher uptake ofgeneric medicines will conspire to keep longer term growth steady, boosted by upward volume changes,with the patented drug market ...
|
more...
|
$1,175.00
|
Slovakia Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... this is realised. We do not expect either of the two private insurers - Dôvera or DutchownedUnion - will surrender their businesses without a fight, with Union in particular well-placedto oppose the move, potentially invoking ...
|
more...
|
$1,175.00
|
Morocco Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... the evidence ofbribery and corruption, and the shortage of doctors in the sector. BMI believes the commitment toimprove governance and implement controls in the sector will be fulfilled in the medium-to-long term. Assuch, we maintain ...
|
more...
|
$1,175.00
|
Singapore Healthcare Industry 2H12
1/14/2013 | published by: Emerging Markets Direct Reports
... centric initiative, and national electronic health records, plus the profile, comparative matrix and SWOT of the industry leading players: Parkway Holdings Ltd (Parkway), Thomson Medical Centre (TMC), Health Management International Ltd (HMI), and China Healthcare ...
|
more...
|
$480.00
|
Indonesia Pharmaceuticals & Healthcare Industry 2H12
1/14/2013 | published by: Emerging Markets Direct Reports
... support and pharmaceutical trade. It also covers the market trends and outlook, regulatory changes, counterfeit drugs, industry SWOT analysis and market outlook, plus profile, comparative matrix and SWOT analysis of the leading players: PT Kalbe ...
|
more...
|
$450.00
|
|
|
$4,650.00
|
The U.S. Market for Rx to OTC Switches, 6th Edition
1/11/2013 | published by: Kalorama Information
... Kalorama Information has analyzed the market for drugs with switched ingredients in detail. The market is fueled by several factors including an aging population; steady to increased incidences of conditions and diseases; new drug classes ...
|
more...
|
$3,995.00
|
Switzerland Pharmaceuticals and Healthcare Report Q1 2013
1/9/2013 | published by: Business Monitor International
... believes the government needs to do more to alter patients' attitudestowards these drugs as this is the main growth deterrent. Headline Expenditure Projections Pharmaceuticals: CHF6.77bn (US$7.63bn) in 2011 to CHF6.58bn (US$7.00bn) in 2012; -2.8% declinein ...
|
more...
|
$1,175.00
|
Incontinence in Slovenia
1/8/2013 | published by: Euromonitor International
... embarrassing condition. As is the case in much of Europe, Slovenia is a rapidly ageing society. According to the 2011 report “Ageing in Slovenia”, produced by the Statistical Office of Slovenia, from 1989 to 2009 ...
|
more...
|
$900.00
|
Triple Analysis: Lymphoma, Angiogenesis and Peptides
1/7/2013 | published by: BioSeeker Group AB
... standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but ...
|
more...
|
$5,175.00
|
|
|
$5,175.00
|
Triple Analysis: Melanoma, Prostate Cancer and Peptides
1/7/2013 | published by: BioSeeker Group AB
... a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different ...
|
more...
|
$5,175.00
|
Triple Analysis: Leukemia, Angiogenesis and Peptides
1/7/2013 | published by: BioSeeker Group AB
... standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but ...
|
more...
|
$5,175.00
|
Triple Analysis: Lung Cancer, Pancreatic Cancer and Peptides
1/7/2013 | published by: BioSeeker Group AB
... in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between ...
|
more...
|
$5,175.00
|
|
|
$5,175.00
|
Triple Analysis: Melanoma, Antibodies and Peptides
1/7/2013 | published by: BioSeeker Group AB
... five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas. ...
|
more...
|
$5,175.00
|
< prev 1 2 3 4 5 6 7 8 9 10 next >
|